Shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) have been assigned a consensus recommendation of “Hold” from the six research firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $6.33.
APTO has been the topic of a number of analyst reports. Zacks Investment Research downgraded Aptose Biosciences from a “hold” rating to a “sell” rating in a research report on Tuesday, January 16th. HC Wainwright set a $6.00 price objective on Aptose Biosciences and gave the stock a “buy” rating in a research report on Wednesday, March 7th. Finally, ValuEngine cut Aptose Biosciences from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st.
A hedge fund recently raised its stake in Aptose Biosciences stock. Acadian Asset Management LLC increased its stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 316.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,421 shares of the biotechnology company’s stock after purchasing an additional 33,766 shares during the quarter. Acadian Asset Management LLC owned 0.17% of Aptose Biosciences worth $100,000 at the end of the most recent quarter. 1.05% of the stock is owned by institutional investors.
Aptose Biosciences stock traded up $0.13 during trading on Monday, reaching $3.31. 127,746 shares of the company were exchanged, compared to its average volume of 392,932. Aptose Biosciences has a 52-week low of $1.00 and a 52-week high of $3.97. The company has a market cap of $97.33, a price-to-earnings ratio of -6.12 and a beta of 2.38.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.